Organization
Prince of Wales Hospital
14 abstracts
Abstract
Health-related quality of life (HRQoL) in the phase 3 KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) versus placebo plus gem/cis for advanced biliary tract cancer (BTC).Org: Asan Medical Center, University of California Los Angeles, University of California Irvine, Hannover Medical School, Zhongshan Hospital,
Abstract
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.Org: University Hospital of Cologne, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), German Hodgkin Study Group (GHSG), Swiss Group for Clinical Cancer Research (SAKK), Department of Internal Medicine III with Hematology,
Abstract
Impact of artificial intelligence (AI) decision support on clinical trial participation: A before-after implementation study on a nationwide molecular tumor board.Org: NHMRC Clinical Trials Centre, The University of Sydney, Garvan Institute of Medical Research, Prince of Wales Hospital, The NHMRC Clinical Trials Centre,
Abstract
The TAC-GReD trial: The combination of talazoparib and carboplatin in DNA damage repair deficient recurrent high-grade glioma.Org: Department of Clinical Oncology, Queen Elizabeth Hospital, LKS Faculty of Medicine, University of Hong Kong, Department of Neurosurgery, Prince of Wales Hospital, Prince of Wales Hospital,
Abstract
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC.Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, National Cancer Centre Singapore, Department of Clinical Oncology, Queen Elizabeth Hospital, The Chinese University of Hong Kong, Prince of Wales Hospital,
Abstract
Plasma lipidomic profiling of chemotherapy-induced peripheral neuropathy.Org: Garvan Institute of Medical Research, Brain and Mind Centre, The University of Sydney, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Prince of Wales Hospital,
Abstract
Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.Org: NHMRC Clinical Trials Centre, The University of Sydney, Peter MacCallum Cancer Centre, Melbourne, Australia, Western Health, Mater Cancer Care Centre,
Abstract
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer—Toxicity and interim efficacy data.Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Walter & Eliza Hall Institute of Medical Research and Western Health, Melbourne, Australia, Alfred Hospital Melbourne, Monash Cancer Centre, Royal North Shore Hospital, Sydney, Australia,
Abstract
Genomic therapy matching in rare and refractory cancers: Updated results from a retrospective cohort study in the Molecular Screening and Therapeutic (MoST) program.Org: NHMRC Clinical Trials Centre, The University of Sydney, Garvan Institute of Medical Research, The NHMRC Clinical Trials Centre, Rare Cancer Laboratory,
Abstract
Preliminary results of sequential transarterial chemoembolization and stereotactic body radiotherapy followed by immunotherapy using single tremelimumab regular interval durvalumab in locally advanced, unresectable hepatocellular carcinoma (START-FIT using STRIDE): A single-arm, phase II study.Org: The University of Hong Kong, The Chinese University of Hong Kong, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Tuen Mun Hospital, University of Hong Kong,
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.Org: Austin Health and Peter MacCallum Cancer Centre, Melbourne, Australia, Garvan Institute of Medical Research, Sydney, Australia, The Kinghorn Cancer Centre,
Abstract
Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial.Org: National University Cancer Institute, Singapore, Saw Swee Hock School of Public Health, National University of Singapore, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Department of Medical Oncology, Tan Tock Seng Hospital, Singapore, Singapore, National Cancer Centre Singapore,
Abstract
Long-term clinical and psychosocial outcomes of surveillance in Li Fraumeni syndrome.Org: Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, Australian Catholic University, Sydney, NSW, Australia, Peter MacCallum Cancer Centre, Melbourne, Australia,